Search
Foghorn Therapeutics Inc.
FHTXAdd to Watchlist
4.525USD
-0.215-4.54%
Close 07-31 16:00（ET）Quotes delayed by 15 min
265.66MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Foghorn Therapeutics Inc. is 9.00, ranking 16 out of 385 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 14.00 and a low of 9.00.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
11.444
Target Price
+141.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Foghorn Therapeutics Inc.
FHTX
10
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Foghorn Therapeutics Inc.'s expected revenue for the next quarter?
Foghorn Therapeutics Inc.'s expected revenue is 6.00M.
What is Foghorn Therapeutics Inc.'s price target?
Analysts forecast that Foghorn Therapeutics Inc.'s price target is USD 12.00, with the highest forecast at USD 14.00 and the lowest forecast at USD 9.00.
How have Foghorn Therapeutics Inc.FHTX's recent earnings per share performed?
The market expectation was USD -0.29, while Foghorn Therapeutics Inc.FHTX's earnings per share (EPS) for the previous quarter was USD -0.34. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for Foghorn Therapeutics Inc.?
Based on the ratings of Foghorn Therapeutics Inc.'s stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.